Impact of pain and nonpain co-morbidities on opioid use in women with endometriosis
| Autor: | Ahmed M. Soliman, Jamie B Vora, Beverly Johns, Stephanie J. Estes, Georgine Lamvu |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
medicine.medical_specialty
Narcotic medicine.medical_treatment Endometriosis Pain Pharmacy 03 medical and health sciences 0302 clinical medicine Internal medicine medicine Humans In patient 030212 general & internal medicine Retrospective Studies 030219 obstetrics & reproductive medicine business.industry Health Policy Opioid use medicine.disease Analgesics Opioid Opioid Relative risk Female Co morbidity Morbidity business medicine.drug |
| Zdroj: | Journal of Comparative Effectiveness Research. 10:17-27 |
| ISSN: | 2042-6313 2042-6305 |
| DOI: | 10.2217/cer-2020-0181 |
| Popis: | Aim: To evaluate impact of co-morbidities on opioid use in endometriosis. Patients & m ethods: This was a retrospective analysis of data obtained from the Symphony Health database (July 2015–June 2018), which contains medical and pharmacy claims information on 79,947 women with endometriosis. Relative risk (RR) of postdiagnosis opioid use and supply duration associated with baseline co-morbidities were determined. Results: Women with endometriosis using opioids at baseline were 61% more likely to receive opioids postdiagnosis (RR: 1.61; 95% CI: 1.59–1.63). Risk of prolonged opioid supply postdiagnosis was highest for those with prolonged supply at baseline (RR: 21.14; 20.14–22.19), and was 1.32 (1.26–1.38) for patients with ≥1 co-morbidity, 1.37 (1.31–1.43) for pain co-morbidities and 1.07 (1.04–1.11) for psychiatric co-morbidities. Conclusion: Risk of opioid use after endometriosis diagnosis was greater in patients who used opioids before diagnosis. Risk of prolonged opioid use was greater if co-morbidities existed before diagnosis. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|